Core Scientific, Inc./tx
CORZ Nasdaq· Finance Services
Last close · Oct 26, 2026
$13.51
KIRA · Stoqly’s AI analyst, in plain words
- Core Scientific, Inc./tx had $319M of revenue in fiscal 2025, down 37.5% on the year before. Over five years, revenue changed +39.5% a year on average.
- Its operating margin was −77.0%, down 49.2 pts: of every 100 in sales, about −77 is left after running the business.
- Core Scientific, Inc./tx lost $289M in fiscal 2025.
- Free cash flow was −$451M in fiscal 2025, −141.3% of revenue.
- Core Scientific, Inc./tx owes $750M more than it holds in cash.
Market cap
$4.4B
P/E
—
Revenue
$319M
Net income
−$289M
Free cash flow
−$451M
Operating margin
−77.0%
Core Scientific, Inc./tx in 30 seconds · fiscal 2025
Are sales growing?
−37.5%
No. Sales fell 37.5% last year.
Does it make a profit?
−90.5%
No. It lost money last year.
Does profit turn into cash?
−141.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Core Scientific, Inc./tx does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Core Scientific, Inc./tx
- CIK
- 0001839341
Core Scientific, Inc./tx · CORZ
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $544M | $640M | $502M | $511M | $319M |
| Revenue growth | 802.7% | 17.6% | −21.5% | 1.6% | −37.5% |
| Gross margin | 43.9% | 1.3% | 24.6% | 23.7% | 11.9% |
| Operating margin | 24.2% | −329.5% | 1.8% | −27.8% | −77.0% |
| Net income | $47.3M | −$2.1B | −$246M | −$1.4B | −$289M |
| Net margin | 8.7% | −335.2% | −49.1% | −281.6% | −90.5% |
| Diluted EPS | $0.20 | −$6.30 | −$0.65 | −$4.87 | −$0.88 |
| Cash | |||||
| Cash from operations | −$56.7M | $205M | $65.1M | $42.9M | $278M |
| Capital expenditure | $0.0M | $384M | $16.2M | $95.0M | $729M |
| Free cash flow | −$56.7M | −$179M | $49.0M | −$52.1M | −$451M |
| FCF margin | −10.4% | −27.9% | 9.7% | −10.2% | −141.3% |
| Share buybacks | — | $31.6M | $0.0M | $0.0M | — |
| Share count change | 48.0% | 46.0% | 11.5% | −32.7% | 24.3% |
| Debt and strength | |||||
| Cash and short-term investments | $118M | $15.9M | $50.4M | $836M | $311M |
| Debt incl. finance leases | — | — | — | — | $1.1B |
| Shareholders' equity | $1.3B | −$409M | −$597M | −$943M | −$963M |
| Current ratio | 2.4x | 0.5x | 0.2x | 6.7x | 1.1x |
| Returns and quality | |||||
| Return on equity | 6.6% | −460.7% | — | — | — |
| Return on tangible equity | 17.1% | — | — | — | — |
| Piotroski F-score | 3 | 3 | 4 | 4 | 3 |
| Altman Z'' | 2.8 | −27.5 | −15.1 | −6.2 | −6.4 |
Insiders bought, 12 months
$0.6M
2 insiders
Insiders sold, 12 months
$6.2M
1 insider
Of sales under plans
100%
$6.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Core Scientific, Inc./tx · CORZ
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $13.51 a share, the company is worth $4.4B.
Source: SEC EDGAR XBRL filings (CIK 0001839341). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.